{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:02Z","timestamp":1792686062243,"version":"4.5.0"},"reference-count":335,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07737-7","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:25:45Z","timestamp":1770261945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting urological cancers with CAR-T cell therapy: current landscape and future directions"],"prefix":"10.1186","volume":"24","author":[{"given":"Kai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilinaer","family":"Wusiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koo Han","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lede","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8587-6959","authenticated-orcid":false,"given":"Dechao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"12","key":"7737_CR1","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, et al. National and subnational trends in cancer burden in China, 2005-20. An analysis of national mortality surveillance data. Lancet Public Health. 2023;8(12):e943\u201355.","journal-title":"Lancet Public Health"},{"issue":"5","key":"7737_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM, Comp\u00e9rat EM, Gill AJ, Hartmann A, et al. The 2022 world Health organization Classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol. 2022;82(5):469\u201382.","journal-title":"Eur Urol"},{"issue":"3","key":"7737_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7737_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s12885-025-13902-w","volume":"25","author":"N Zhou","year":"2025","unstructured":"Zhou N, Bai H, Zhang Z, Yu B, Zhao H, Li J, et al. Global, regional, and national burden of kidney cancer and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projections to 2040. BMC Cancer. 2025;25(1):481.","journal-title":"BMC Cancer"},{"issue":"12","key":"7737_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose TL, Kim WY. Renal cell carcinoma: a Review. Jama. 2024;332(12):1001\u201310.","journal-title":"Jama"},{"issue":"5","key":"7737_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"van Hoogstraten Lmc","year":"2023","unstructured":"van Hoogstraten LMG, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20(5):287\u2013304.","journal-title":"Nat Rev Clin Oncol"},{"key":"7737_CR7","doi-asserted-by":"crossref","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. Update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84(2):191\u2013206.","DOI":"10.1016\/j.eururo.2023.04.021"},{"issue":"1","key":"7737_CR8","first-page":"64","volume":"11","author":"H Zi","year":"2024","unstructured":"Zi H, Liu MY, Luo LS, Huang Q, Luo PC, Luan HH, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. 2024;11(1):64.","journal-title":"Mil Med Res"},{"issue":"1","key":"7737_CR9","first-page":"12","volume":"12","author":"DC Feng","year":"2025","unstructured":"Feng DC, Li DX, Wu RC, Wang J, Xiao YH, Yoo KH, et al. Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Mil Med Res. 2025;12(1):12.","journal-title":"Mil Med Res"},{"issue":"3","key":"7737_CR10","doi-asserted-by":"publisher","first-page":"e251201","DOI":"10.1001\/jamanetworkopen.2025.1201","volume":"8","author":"ZI Ozay","year":"2025","unstructured":"Ozay ZI, Jo Y, Galarza Fortuna G, Hage Chehade C, Gebrael G, Ostrowski M, et al. Treatment and attrition trends for metastatic clear cell renal cell carcinoma in the US. JAMA Netw Open. 2025;8(3):e251201.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7737_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2011.03.047","volume":"60","author":"C Bosetti","year":"2011","unstructured":"Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol. 2011;60(1):1\u201315.","journal-title":"Eur Urol"},{"key":"7737_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","volume":"262","author":"WB Coley","year":"1991","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;262:3\u201311.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"7737_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/oxfordjournals.aje.a121646","volume":"9","author":"R Pearl","year":"1929","unstructured":"Pearl R. Cancer and Tuberculosis*. Am J Epidemiol. 1929;9(1):97\u2013159.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"7737_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38\u201340.","journal-title":"J Urol"},{"issue":"1","key":"7737_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000472047","volume":"3","author":"JA Martinez-Pi\u00f1eiro","year":"1977","unstructured":"Martinez-Pi\u00f1eiro JA, Munta\u00f1ola P. Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report. Eur Urol. 1977;3(1):11\u201322.","journal-title":"Eur Urol"},{"issue":"17","key":"7737_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205\u201309.","journal-title":"N Engl J Med"},{"issue":"6","key":"7737_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 Guidelines Update. Eur Urol. 2024;86(6):531\u201349.","journal-title":"Eur Urol"},{"issue":"23","key":"7737_CR18","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-24-1595","volume":"30","author":"P Isaacsson Velho","year":"2024","unstructured":"Isaacsson Velho P, Bastos DA, Saint\u2019ana PT, Rigatti B, da Costa ET, Muniz DQB, et al. Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects. Clin Cancer Res. 2024;30(23):5342\u201352.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"7737_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"van der Heijden Ms","year":"2023","unstructured":"van der Heijden Ms, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus Gemcitabine-Cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389.","journal-title":"N Engl J Med"},{"issue":"8","key":"7737_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023;24(8):881\u201391.","journal-title":"Lancet Oncol"},{"key":"7737_CR21","doi-asserted-by":"crossref","unstructured":"Pievani A, Biondi M, Tettamanti S, Biondi A, Dotti G, Serafini M. CARs are sharpening their weapons. J ImmunoTher Cancer. 2024;12(1).","DOI":"10.1136\/jitc-2023-008275"},{"issue":"24","key":"7737_CR22","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697\u2013705.","journal-title":"Blood"},{"issue":"16","key":"7737_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"8","key":"7737_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"5","key":"7737_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"11","key":"7737_CR26","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28(11):2320\u201339.","journal-title":"Mol Ther"},{"issue":"5","key":"7737_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40259-019-00368-z","volume":"33","author":"L Springuel","year":"2019","unstructured":"Springuel L, Lonez C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, et al. Chimeric antigen receptor-T cells for targeting solid tumors: current challenges and existing strategies. BioDrugs. 2019;33(5):515\u201337.","journal-title":"BioDrugs"},{"issue":"5","key":"7737_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.21147\/j.issn.1000-9604.2025.05.07","volume":"37","author":"S Huang","year":"2025","unstructured":"Huang S, Zhao Y, Shen J. Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy. Chin J Cancer Res. 2025;37(5):742\u201358.","journal-title":"Chin J Cancer Res"},{"issue":"6","key":"7737_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398.","journal-title":"Nat Med"},{"issue":"14","key":"7737_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395.","journal-title":"N Engl J Med"},{"issue":"11","key":"7737_CR31","doi-asserted-by":"publisher","first-page":"e1511","DOI":"10.1093\/oncolo\/oyae160","volume":"29","author":"R Pichler","year":"2024","unstructured":"Pichler R, Fritz J, Mari A, Cadenar A, von Deimling M, Marcq G, et al. Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncologist. 2024;29(11):e1511\u201322.","journal-title":"Oncologist"},{"key":"7737_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","volume":"294-295","author":"S Narote","year":"2025","unstructured":"Narote S, Desai SA, Patel VP, Deshmukh R, Raut N, Dapse S. Identification of new immune target and signaling for cancer immunotherapy. Cancer Genet. 2025;294-295:57\u201375.","journal-title":"Cancer Genet"},{"key":"7737_CR33","doi-asserted-by":"publisher","first-page":"e18761429273223","DOI":"10.2174\/0118761429273223231124072223","volume":"17","author":"D Karati","year":"2024","unstructured":"Karati D, Kumar D. Molecular Insight into the Apoptotic Mechanism of cancer cells: an explicative Review. Curr Mol Pharmacol. 2024;17:e18761429273223.","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"7737_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960\u201368.","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"7737_CR35","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u201328.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3\u20134","key":"7737_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002620050415","volume":"45","author":"Z Eshhar","year":"1997","unstructured":"Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother. 1997;45(3\u20134):131\u201336.","journal-title":"Cancer Immunol Immunother"},{"key":"7737_CR37","doi-asserted-by":"crossref","unstructured":"Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, et al. The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol. 1996;18(2):199\u2013209.","DOI":"10.1007\/BF00820666"},{"issue":"1","key":"7737_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.178.1.361","volume":"178","author":"P Hwu","year":"1993","unstructured":"Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178(1):361\u201366.","journal-title":"J Exp Med"},{"key":"7737_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J ImmunoTher Cancer. 2017;5:22.","journal-title":"J ImmunoTher Cancer"},{"issue":"20 Pt 1","key":"7737_CR40","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"7737_CR41","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20\u20132.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7737_CR42","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261\u201371.","journal-title":"Blood"},{"issue":"23","key":"7737_CR43","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050\u201356.","journal-title":"Blood"},{"issue":"6","key":"7737_CR44","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie T, Tiruneh GMM, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, Chekol Abebe E. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 2022;18(6):2114254.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"7737_CR45","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","volume":"84","author":"MR Roberts","year":"1994","unstructured":"Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood. 1994;84(9):2878\u201389.","journal-title":"Blood"},{"issue":"6","key":"7737_CR46","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","volume":"161","author":"HM Finney","year":"1998","unstructured":"Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161(6):2791\u201397.","journal-title":"J Immunol"},{"issue":"5","key":"7737_CR47","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822\u201326.","journal-title":"J Clin Invest"},{"issue":"4","key":"7737_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188(4):619\u201326.","journal-title":"J Exp Med"},{"key":"7737_CR49","doi-asserted-by":"crossref","unstructured":"Philipson BI, O\u2019Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci Signal. 2020;13(625).","DOI":"10.1126\/scisignal.aay8248"},{"issue":"6","key":"7737_CR50","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353.","journal-title":"Nat Med"},{"issue":"26","key":"7737_CR51","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323.","journal-title":"Blood"},{"issue":"95","key":"7737_CR52","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.","journal-title":"Sci Transl Med"},{"issue":"19","key":"7737_CR53","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"20","key":"7737_CR54","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.2024027347","volume":"145","author":"JC Chavez","year":"2025","unstructured":"Chavez JC, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303\u201311.","journal-title":"Blood"},{"issue":"6","key":"7737_CR55","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506.","journal-title":"Blood"},{"issue":"3","key":"7737_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with Relapsed\/Refractory Mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555\u201367.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7737_CR57","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory Mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594\u2013606.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7737_CR58","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025;39(5):1058\u201368.","journal-title":"Leukemia"},{"issue":"5","key":"7737_CR59","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.24.00321","volume":"43","author":"GW Roloff","year":"2025","unstructured":"Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, et al. Outcomes after Brexucabtagene autoleucel administered as a standard therapy for adults with Relapsed\/Refractory B-Cell ALL. J Clin Oncol. 2025;43(5):558\u201366.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7737_CR60","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7737_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397.","journal-title":"Blood"},{"issue":"9","key":"7737_CR62","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394.","journal-title":"Nat Med"},{"issue":"11","key":"7737_CR63","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"11","key":"7737_CR64","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene Vicleucel for Relapsed\/Refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol. 2023;41(11):2087\u201397.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7737_CR65","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404\u201316.","journal-title":"Blood"},{"issue":"10402","key":"7737_CR66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet. 2023;402(10402):641\u201354.","journal-title":"Lancet"},{"issue":"8","key":"7737_CR67","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30(8):2199\u2013207.","journal-title":"Nat Med"},{"issue":"10","key":"7737_CR68","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene Maraleucel in Relapsed\/Refractory Mantle cell lymphoma: primary analysis of the Mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42(10):1146\u201357.","journal-title":"J Clin Oncol"},{"issue":"9","key":"7737_CR69","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year Update of tisagenlecleucel in Pediatric and Young adult patients with Relapsed\/Refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664\u201369.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7737_CR70","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"17","key":"7737_CR71","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, et al. Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood. 2024;143(17):1713\u201325.","journal-title":"Blood"},{"key":"7737_CR72","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-pharmtox-010814-124844","volume":"56","author":"G Gross","year":"2016","unstructured":"Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56:59\u201383.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"7737_CR73","doi-asserted-by":"crossref","unstructured":"Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules. 2022;12(9).","DOI":"10.3390\/biom12091303"},{"issue":"1","key":"7737_CR74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","volume":"16","author":"ML Schubert","year":"2023","unstructured":"Schubert ML, Schmitt A, H\u00fcckelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2023;16(1):79.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"7737_CR75","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00262-023-03423-5","volume":"72","author":"A Gu","year":"2023","unstructured":"Gu A, Bai Y, Zhang C, Xu C, An Z, Zhang Y, et al. IL13R\u03b12-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy. Cancer Immunol Immunother. 2023;72(7):2393\u2013403.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"7737_CR76","doi-asserted-by":"publisher","first-page":"10488","DOI":"10.1038\/s41598-022-14523-0","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Gu C, Huang L, Wu H, Shi J, Zhang Z, et al. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep. 2022;12(1):10488.","journal-title":"Sci Rep"},{"key":"7737_CR77","doi-asserted-by":"crossref","unstructured":"Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1).","DOI":"10.1172\/jci.insight.96976"},{"issue":"4","key":"7737_CR78","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3324\/haematol.2019.231183","volume":"106","author":"M Guercio","year":"2021","unstructured":"Guercio M, Orlando D, Di Cecca S, Sinibaldi M, Boffa I, Caruso S, et al. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. Haematologica. 2021;106(4):987\u201399.","journal-title":"Haematologica"},{"issue":"6","key":"7737_CR79","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/2326-6066.CIR-19-0908","volume":"8","author":"D Wijewarnasuriya","year":"2020","unstructured":"Wijewarnasuriya D, Bebernitz C, Lopez AV, Rafiq S, Brentjens RJ. Excessive costimulation Leads to dysfunction of adoptively transferred T cells. Cancer Immunol Res. 2020;8(6):732\u201342.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"7737_CR80","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/mt.2013.192","volume":"21","author":"AA Hombach","year":"2013","unstructured":"Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation\u201d. Mol Ther. 2013;21(12):2268\u201377.","journal-title":"Mol Ther"},{"issue":"1","key":"7737_CR81","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1038\/s41467-024-50251-x","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Wei JS, Cheuk AT, Milewski D, Zhang Z, Kim YY, et al. CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nat Commun. 2024;15(1):6222.","journal-title":"Nat Commun"},{"issue":"8","key":"7737_CR82","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145\u201354.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"7737_CR83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"key":"7737_CR84","doi-asserted-by":"publisher","first-page":"108405","DOI":"10.1016\/j.biotechadv.2024.108405","volume":"75","author":"HK Williamson","year":"2024","unstructured":"Williamson HK, Mendes PM. An integrated perspective on measuring cytokines to inform CAR-T bioprocessing. Biotechnol Adv. 2024;75:108405.","journal-title":"Biotechnol Adv"},{"issue":"11","key":"7737_CR85","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362.","journal-title":"Mol Ther"},{"issue":"1","key":"7737_CR86","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1038\/s41598-022-16616-2","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Li Q, Yan ZX, Sheng LS, Fu D, Xu P, et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci Rep. 2022;12(1):12506.","journal-title":"Sci Rep"},{"issue":"10","key":"7737_CR87","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1535-7163.MCT-16-0111","volume":"15","author":"Y Song","year":"2016","unstructured":"Song Y, Liu Y, Hu R, Su M, Rood D, Lai L. In vivo antitumor activity of a recombinant IL7\/IL15 hybrid cytokine in mice. Mol Cancer Ther. 2016;15(10):2413\u201321.","journal-title":"Mol Cancer Ther"},{"key":"7737_CR88","doi-asserted-by":"crossref","unstructured":"Zhang L, Davies JS, Serna C, Yu Z, Restifo NP, Rosenberg SA, et al. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. J ImmunoTher Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2019-000210"},{"key":"7737_CR89","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru M, O\u2019Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;13:102.","journal-title":"J Transl Med"},{"issue":"6","key":"7737_CR90","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023;29(6):1379\u201388.","journal-title":"Nat Med"},{"issue":"1","key":"7737_CR91","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118.","journal-title":"J Hematol Oncol"},{"key":"7737_CR92","doi-asserted-by":"crossref","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133(9).","DOI":"10.1172\/JCI166028"},{"issue":"1","key":"7737_CR93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol Cancer. 2023;22(1):131.","journal-title":"Mol Cancer"},{"issue":"23","key":"7737_CR94","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341\u201355.","journal-title":"Oncotarget"},{"issue":"5","key":"7737_CR95","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther. 2017;25(5):1248\u201358.","journal-title":"Mol Ther"},{"issue":"7903","key":"7737_CR96","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934\u201341.","journal-title":"Nature"},{"issue":"4","key":"7737_CR97","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334.","journal-title":"Nat Med"},{"issue":"1","key":"7737_CR98","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"5","key":"7737_CR99","first-page":"265","volume":"48","author":"J Peter","year":"2025","unstructured":"Peter J, Toppeta F, Trubert A, Danhof S, Hudecek M, D\u00e4ullary T. Multi-targeting CAR-T cell strategies to overcome immune evasion in lymphoid and myeloid malignancies. Oncol Res Treat. 2025;48(5):265\u201379.","journal-title":"Oncol Res Treat"},{"issue":"3","key":"7737_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"7952","key":"7737_CR101","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507\u201316.","journal-title":"Nature"},{"issue":"10","key":"7737_CR102","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","volume":"22","author":"M Verma","year":"2023","unstructured":"Verma M, Obergfell K, Topp S, Panier V, Wu J. The next-generation CAR-T therapy landscape. Nat Rev Drug Discov. 2023;22(10):776\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"7737_CR103","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"7737_CR104","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41598-021-82700-8","volume":"11","author":"H Kim","year":"2021","unstructured":"Kim H, Kim JK, Ye C, Choi JH, Lee H, Oh JJ, et al. Recurrence after radical and partial nephrectomy in high complex renal tumor using propensity score matched analysis. Sci Rep. 2021;11(1):2919.","journal-title":"Sci Rep"},{"issue":"3","key":"7737_CR105","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79\u201387.","journal-title":"World J Oncol"},{"issue":"10451","key":"7737_CR106","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404(10451):476\u201391.","journal-title":"Lancet"},{"issue":"1","key":"7737_CR107","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.drudis.2021.07.009","volume":"27","author":"O Pontes","year":"2022","unstructured":"Pontes O, Oliveira-Pinto S, Baltazar F, Costa M. Renal cell carcinoma therapy: current and new drug candidates. Drug Discov Today. 2022;27(1):304\u201314.","journal-title":"Drug Discov Today"},{"issue":"9","key":"7737_CR108","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.2000.18.9.1928","volume":"18","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18(9):1928\u201335.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7737_CR109","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.1992.10.7.1124","volume":"10","author":"DH Ilson","year":"1992","unstructured":"Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol. 1992;10(7):1124\u201330.","journal-title":"J Clin Oncol"},{"issue":"23","key":"7737_CR110","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","volume":"375","author":"A Ravaud","year":"2016","unstructured":"Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246\u201354.","journal-title":"N Engl J Med"},{"issue":"10032","key":"7737_CR111","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","volume":"387","author":"NB Haas","year":"2016","unstructured":"Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008\u201316.","journal-title":"Lancet"},{"issue":"8","key":"7737_CR112","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"7737_CR113","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552\u201362.","journal-title":"Lancet Oncol"},{"issue":"9637","key":"7737_CR114","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"25","key":"7737_CR115","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","volume":"25","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, et al. Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25(25):3958\u201364.","journal-title":"J Clin Oncol"},{"issue":"8","key":"7737_CR116","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391(8):710\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"7737_CR117","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2023;20(3):133\u201357.","journal-title":"Nat Rev Urol"},{"issue":"19","key":"7737_CR118","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"8","key":"7737_CR119","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant Pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"7737_CR120","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an anti-Programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune Correlates from a phase ia study. J Clin Oncol. 2016;34(8):833\u201342.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7737_CR121","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"7737_CR122","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41467-024-45216-z","volume":"15","author":"Y Zakharia","year":"2024","unstructured":"Zakharia Y, Singer EA, Acharyya S, Garje R, Joshi M, Peace D, et al. Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib\/II study BTCRC-GU16-043. Nat Commun. 2024;15(1):972.","journal-title":"Nat Commun"},{"issue":"6","key":"7737_CR123","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology Guidelines on renal cell carcinoma: the 2025 Update. Eur Urol. 2025;87(6):683\u201396.","journal-title":"Eur Urol"},{"issue":"2","key":"7737_CR124","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","volume":"87","author":"R Barragan-Carrillo","year":"2025","unstructured":"Barragan-Carrillo R, Saad E, Saliby RM, Sun M, Albiges L, Bex A, et al. First and second-line treatments in metastatic renal cell carcinoma. Eur Urol. 2025;87(2):143\u201354.","journal-title":"Eur Urol"},{"issue":"1","key":"7737_CR125","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","volume":"58","author":"AB Stillebroer","year":"2010","unstructured":"Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58(1):75\u201383.","journal-title":"Eur Urol"},{"issue":"3","key":"7737_CR126","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1042\/BST20160037","volume":"44","author":"CH Lamers","year":"2016","unstructured":"Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem Soc Trans. 2016;44(3):951\u201359.","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"7737_CR127","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"key":"7737_CR128","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.omto.2021.12.019","volume":"24","author":"Y Wang","year":"2022","unstructured":"Wang Y, Buck A, Grimaud M, Culhane AC, Kodangattil S, Razimbaud C, et al. Anti-CAIX BB\u03b6 CAR4\/8 T cells exhibit superior efficacy in a ccRCC mouse model. Mol Ther Oncolytics. 2022;24:385\u201399.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"7737_CR129","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 2024;23(1):56.","journal-title":"Mol Cancer"},{"issue":"1","key":"7737_CR130","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12943-025-02446-z","volume":"24","author":"Y Su","year":"2025","unstructured":"Su Y, Yang G, Chen B, Qian Y, Ma W, Jiang X, et al. Enhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-\u03baB signaling. Mol Cancer. 2025;24(1):289.","journal-title":"Mol Cancer"},{"key":"7737_CR131","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai L, Xu A, Xu J. Roles of PD-1\/PD-L1 pathway: signaling, cancer, and Beyond. Adv Exp Med Biol. 2020;1248:33\u201359.","journal-title":"Adv Exp Med Biol"},{"key":"7737_CR132","doi-asserted-by":"crossref","unstructured":"de Campos Nsp, de Oliveira Beserra A, Pereira PHB, Chaves AS, Fonseca FLA, da Silva Medina T, et al. Immune checkpoint blockade via PD-L1 potentiates more CD28-based than 4-1BB-Based anti-carbonic anhydrase IX chimeric antigen receptor T cells. Int J Mol Sci. 2022;23(10).","DOI":"10.3390\/ijms23105448"},{"issue":"2","key":"7737_CR133","doi-asserted-by":"publisher","first-page":"108879","DOI":"10.1016\/j.isci.2024.108879","volume":"27","author":"Y Wang","year":"2024","unstructured":"Wang Y, Cho JW, Kastrunes G, Buck A, Razimbaud C, Culhane AC, et al. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. iScience. 2024;27(2):108879.","journal-title":"iScience"},{"issue":"1","key":"7737_CR134","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-med-070623-045906","volume":"76","author":"PD Zang","year":"2025","unstructured":"Zang PD, Angeles A, Pal SK. CD70: an emerging anticancer target in renal cell carcinoma and Beyond. Annu Rev Med. 2025;76(1):257\u201366.","journal-title":"Annu Rev Med"},{"issue":"1","key":"7737_CR135","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","volume":"41","author":"T Flieswasser","year":"2022","unstructured":"Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12.","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"7737_CR136","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","volume":"82","author":"SH Panowski","year":"2022","unstructured":"Panowski SH, Srinivasan S, Tan N, Tacheva-Grigorova SK, Smith B, Mak YSL, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma. Cancer Res. 2022;82(14):2610\u201324.","journal-title":"Cancer Res"},{"issue":"17","key":"7737_CR137","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"key":"7737_CR138","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","volume":"14","author":"X Tang","year":"2019","unstructured":"Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics. 2019;14:279\u201387.","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"7737_CR139","doi-asserted-by":"publisher","first-page":"102321","DOI":"10.1016\/j.xcrm.2025.102321","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Hu J, Li Z, Zhu E, Chen Y, Halladay T, et al. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med. 2025;6(9):102321.","journal-title":"Cell Rep Med"},{"issue":"3","key":"7737_CR140","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 2019;68(3):365\u201377.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"7737_CR141","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen J, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-targeted allogeneic CAR T-Cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 2024;14(7):1176\u201389.","journal-title":"Cancer Discov"},{"issue":"4","key":"7737_CR142","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/cas.14835","volume":"112","author":"JI Mori","year":"2021","unstructured":"Mori JI, Adachi K, Sakoda Y, Sasaki T, Goto S, Matsumoto H, et al. Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. Cancer Sci. 2021;112(4):1417\u201328.","journal-title":"Cancer Sci"},{"issue":"11","key":"7737_CR143","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/0008-5472.CAN-11-3062","volume":"72","author":"S Nishizawa","year":"2012","unstructured":"Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res. 2012;72(11):2844\u201354.","journal-title":"Cancer Res"},{"issue":"5","key":"7737_CR144","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41416-022-02100-1","volume":"128","author":"Y Watanabe","year":"2023","unstructured":"Watanabe Y, Tsukahara T, Murata K, Hamada S, Kubo T, Kanaseki T, et al. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours. Br J Cancer. 2023;128(5):886\u201395.","journal-title":"Br J Cancer"},{"key":"7737_CR145","doi-asserted-by":"crossref","unstructured":"Weber J, Rade M, Michael J, Tony LT, Freitag F, Spieler P, et al. ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell Rep Med. 2025;102400.","DOI":"10.1016\/j.xcrm.2025.102400"},{"issue":"1","key":"7737_CR146","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24(1):133.","journal-title":"Cancer Cell Int"},{"key":"7737_CR147","doi-asserted-by":"publisher","first-page":"175883592090750","DOI":"10.1177\/1758835920907504","volume":"12","author":"E Rassy","year":"2020","unstructured":"Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920907504.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"7737_CR148","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CJI.0000000000000301","volume":"43","author":"H Li","year":"2020","unstructured":"Li H, Ding J, Lu M, Liu H, Miao Y, Li L, et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J Immunother. 2020;43(1):16\u201328.","journal-title":"J Immunother"},{"key":"7737_CR149","doi-asserted-by":"publisher","first-page":"150781","DOI":"10.1016\/j.bbrc.2024.150781","volume":"734","author":"Q Li","year":"2024","unstructured":"Li Q, Yang L, Li S, Zhao W, Xue Y, Lu Z, et al. Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment. Biochem Biophys Res Commun. 2024;734:150781.","journal-title":"Biochem Biophys Res Commun"},{"key":"7737_CR150","doi-asserted-by":"publisher","first-page":"105829","DOI":"10.1016\/j.phrs.2021.105829","volume":"174","author":"M Lu","year":"2021","unstructured":"Lu M, Zhang X, Gao X, Sun S, Wei X, Hu X, et al. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. Pharmacol Res. 2021;174:105829.","journal-title":"Pharmacol Res"},{"issue":"2","key":"7737_CR151","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339.","journal-title":"Trends Cancer"},{"key":"7737_CR152","doi-asserted-by":"publisher","first-page":"106701","DOI":"10.1016\/j.phrs.2023.106701","volume":"189","author":"L Fang","year":"2023","unstructured":"Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, et al. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res. 2023;189:106701.","journal-title":"Pharmacol Res"},{"key":"7737_CR153","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2021.11.018","volume":"24","author":"C Zhang","year":"2022","unstructured":"Zhang C, Fang L, Wang X, Yuan S, Li W, Tian W, et al. Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma. Mol Ther Oncolytics. 2022;24:14\u201325.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"7737_CR154","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","volume":"14","author":"F Ji","year":"2021","unstructured":"Ji F, Zhang F, Zhang M, Long K, Xia M, Lu F, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021;14(1):152.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"7737_CR155","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi Y, Kotchetkov IS, Dobrin A, Hanina SA, Rajasekhar VK, Healey JH, et al. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther. 2024;32(7):2393\u2013405.","journal-title":"Mol Ther"},{"issue":"1","key":"7737_CR156","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s12672-025-03040-x","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang H, Li Y, Ma X, Tan H, Gao J, et al. Disease burden and trends of bladder cancer in the world and BRICS from 1990 to 2021 and its projection until 2036: analysis based on the global burden of disease study 2021. Discov Oncol. 2025;16(1):1319.","journal-title":"Discov Oncol"},{"issue":"4","key":"7737_CR157","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 amendment. J Urol. 2024;211(4):533\u201338.","journal-title":"J Urol"},{"issue":"6","key":"7737_CR158","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","volume":"86","author":"R Li","year":"2024","unstructured":"Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, et al. Bladder-sparing therapy for Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: International bladder cancer group Recommendations for optimal sequencing and patient selection. Eur Urol. 2024;86(6):516\u201327.","journal-title":"Eur Urol"},{"issue":"5","key":"7737_CR159","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"van der Heijden Ag","year":"2025","unstructured":"van der Heijden Ag, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat, Dimitropoulos K, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines. Eur Urol. 2025;87(5):582\u2013600.","journal-title":"Eur Urol"},{"issue":"5","key":"7737_CR160","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"7737_CR161","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Souli\u00e9 M, Guy L, Laguerre B, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary Endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021;79(2):214\u201321.","journal-title":"Eur Urol"},{"issue":"2","key":"7737_CR162","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14872","volume":"125","author":"A Martini","year":"2020","unstructured":"Martini A, Sfakianos JP, Renstr\u00f6m-Koskela L, Mortezavi A, Falagario UG, Egevad L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2020;125(2):270\u201375.","journal-title":"BJU Int"},{"key":"7737_CR163","doi-asserted-by":"crossref","unstructured":"Hayashi T, Fujita K, Hayashi Y, Hatano K, Kawashima A, McConkey DJ, et al. Mutational landscape and environmental effects in bladder cancer. Int J Mol Sci. 2020;21(17).","DOI":"10.3390\/ijms21176072"},{"issue":"2","key":"7737_CR164","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u201383.","journal-title":"J Urol"},{"issue":"1","key":"7737_CR165","doi-asserted-by":"publisher","first-page":"e0019423","DOI":"10.1128\/cmr.00194-23","volume":"38","author":"GD Liatsos","year":"2025","unstructured":"Liatsos GD, Mariolis I, Hadziyannis E, Bamias A, Vassilopoulos D. Review of BCG immunotherapy for bladder cancer. Clin Microbiol Rev. 2025;38(1):e0019423.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"7737_CR166","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, et al. Final results of neoadjuvant Atezolizumab in Cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212\u201322.","journal-title":"Eur Urol"},{"issue":"11","key":"7737_CR167","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29(11):2825\u201334.","journal-title":"Nat Med"},{"issue":"13","key":"7737_CR168","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"7737_CR169","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","volume":"82","author":"K Meghani","year":"2022","unstructured":"Meghani K, Cooley LF, Choy B, Kocherginsky M, Swaminathan S, Munir SS, et al. First-in-human intravesical delivery of Pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin. Eur Urol. 2022;82(6):602\u201310.","journal-title":"Eur Urol"},{"issue":"1","key":"7737_CR170","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.clgc.2023.09.010","volume":"22","author":"N Milloy","year":"2024","unstructured":"Milloy N, Kirker M, Unsworth M, Montgomery R, Kluth C, Kearney M, et al. Real-world analysis of treatment patterns and platinum-based treatment eligibility of patients with metastatic urothelial cancer in 5 European countries. Clin Genitourin Cancer. 2024;22(1):e136\u201347.1.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"7737_CR171","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41416-023-02543-0","volume":"130","author":"RJ Jones","year":"2024","unstructured":"Jones RJ, Crabb SJ, Linch M, Birtle AJ, McGrane J, Enting D, et al. Systemic anticancer therapy for urothelial carcinoma: UK oncologists\u2019 perspective. Br J Cancer. 2024;130(6):897\u2013907.","journal-title":"Br J Cancer"},{"issue":"4","key":"7737_CR172","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.eururo.2022.09.003","volume":"83","author":"SS Sridhar","year":"2023","unstructured":"Sridhar SS, North SA, Blais N. Predictive biomarkers in muscle invasive bladder cancer: are we there yet? Eur Urol. 2023;83(4):318\u201319.","journal-title":"Eur Urol"},{"issue":"40","key":"7737_CR173","doi-asserted-by":"publisher","first-page":"e2400156","DOI":"10.1002\/advs.202400156","volume":"11","author":"M Ding","year":"2024","unstructured":"Ding M, Lin J, Qin C, Fu Y, Du Y, Qiu X, et al. Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer. Adv Sci (Weinh). 2024;11(40):e2400156.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"7737_CR174","doi-asserted-by":"publisher","first-page":"e1248","DOI":"10.1002\/cti2.1248","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu L, Li Z, Mei H, Li W, Chen D, Liu L, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunol. 2021;10(2):e1248.","journal-title":"Clin Transl Immunol"},{"issue":"25","key":"7737_CR175","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab vedotin with or without Pembrolizumab in Cisplatin-ineligible patients with Previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41(25):4107\u201317.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7737_CR176","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab vedotin plus Pembrolizumab in Previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7737_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15212\/bioi-2025-0041","volume":"6","author":"J Niu","year":"2025","unstructured":"Niu J, Liu G, Zhang S, Xu C, Xu Z, Ma X, et al. Novel CAR-T cells specifically targeting Nectin4 exhibit effective anti-tumor efficacy in bladder cancer cell lines. BIO Integration. 2025;6(1):1\u201311.","journal-title":"Bio Integration"},{"issue":"16_suppl","key":"7737_CR178","doi-asserted-by":"publisher","first-page":"e14574","DOI":"10.1200\/JCO.2024.42.16_suppl.e14574","volume":"42","author":"J Shen","year":"2024","unstructured":"Shen J, Dai D, Zhao W, Liu T, Zhao Y, Xu Y, et al. A novel co-receptor with mutated TIGIT to enhance PSCA CAR-T therapy for bladder cancer. J Clin Oncol. 2024;42(16_suppl):e14574.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7737_CR179","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1038\/s44321-024-00153-8","volume":"16","author":"N Khazamipour","year":"2024","unstructured":"Khazamipour N, Oo HZ, Al-Nakouzi N, Marzban M, Khazamipour N, Roberts ME, et al. Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors. EMBO Mol Med. 2024;16(11):2775\u201394.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"7737_CR180","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/imm.13187","volume":"160","author":"G Parriott","year":"2020","unstructured":"Parriott G, Deal K, Crean S, Richardson E, Nylen E, Barber A. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer. Immunology. 2020;160(3):280\u201394.","journal-title":"Immunology"},{"key":"7737_CR181","doi-asserted-by":"publisher","first-page":"153303382513368","DOI":"10.1177\/15330338251336850","volume":"24","author":"H Yang","year":"2025","unstructured":"Yang H, Zhang Y, Li Y, Peng S, An R, Du N, et al. Bispecific c-Met\/PD-1 CAR-T cells have enhanced therapeutic effects on solid tumor. Technol Cancer Res Treat. 2025;24:15330338251336850.","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"7737_CR182","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","volume":"88","author":"S Ghodoussipour","year":"2025","unstructured":"Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, et al. A Systematic Review of novel intravesical approaches for the treatment of patients with non-muscle-invasive bladder cancer. Eur Urol. 2025;88(1):33\u201355.","journal-title":"Eur Urol"},{"issue":"2_Supplement","key":"7737_CR183","doi-asserted-by":"publisher","first-page":"B008","DOI":"10.1158\/2326-6074.IO2025-B008","volume":"13","author":"S-Y Liao","year":"2025","unstructured":"Liao S-Y, Wu L-T, Chou J, Lee JK. Abstract B008: development of intravesical adoptive NECTIN4 chimeric antigen receptor (CAR) T cell therapy for non-muscle invasive bladder cancer. Cancer Immunol Res. 2025;13(2_Supplement):B008.","journal-title":"Cancer Immunol Res"},{"issue":"3, Supplement","key":"7737_CR184","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.urolonc.2024.12.242","volume":"43","author":"P Abrahimi","year":"2025","unstructured":"Abrahimi P, Khan J, Duren-Lubanski A, Cai W, Marouf Y, Tallman J, et al. INTRAVESICAL MUC16 TARGETING CAR T CELLS FOR ORGAN-CONFINED BLADDER CANCERS. Urologic Oncol: Semin Original Investigations. 2025;43(3, Supplement):96\u201397.","journal-title":"Urologic Oncol: Semin Original Investigations"},{"key":"7737_CR185","doi-asserted-by":"publisher","first-page":"782448","DOI":"10.3389\/fimmu.2021.782448","volume":"12","author":"CM Grunewald","year":"2021","unstructured":"Grunewald CM, Haist C, K\u00f6nig C, Petzsch P, Bister A, N\u00f6\u00dfner E, et al. Epigenetic priming of bladder cancer cells with decitabine increases cytotoxicity of human EGFR and CD44v6 CAR engineered T-Cells. Front Immunol. 2021;12:782448.","journal-title":"Front Immunol"},{"issue":"628","key":"7737_CR186","doi-asserted-by":"publisher","first-page":"eabg 3072","DOI":"10.1126\/scitranslmed.abg3072","volume":"14","author":"B Greco","year":"2022","unstructured":"Greco B, Malacarne V, De Girardi F, Scotti GM, Manfredi F, Angelino E, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci Transl Med. 2022;14(628):eabg 3072.","journal-title":"Sci Transl Med"},{"issue":"1","key":"7737_CR187","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1038\/s41467-025-62710-0","volume":"16","author":"K Chang","year":"2025","unstructured":"Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, et al. Modulating the PPAR\u03b3 pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun. 2025;16(1):8215.","journal-title":"Nat Commun"},{"issue":"1","key":"7737_CR188","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"7737_CR189","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an Update. Eur Urol. 2025;87(3):302\u201313.","journal-title":"Eur Urol"},{"issue":"2","key":"7737_CR190","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Part II-2024 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"key":"7737_CR191","first-page":"0791","volume":"8","author":"M Cai","year":"2025","unstructured":"Cai M, Zheng F, Ren YZ, Zhen C, Fu D, Song XL, et al. New insights into potential therapeutic targets for neuroendocrine prostate cancer: from bench to clinic. Res (Wash D C). 2025;8:0791.","journal-title":"Res (Wash D C)"},{"issue":"5_suppl","key":"7737_CR192","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO.2025.43.5_suppl.101","volume":"43","author":"AD Raval","year":"2025","unstructured":"Raval AD, Queen VV, Korn MJ, Quintero V, Freedland SJ. Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): a systematic literature review of 35 real-world observational studies. J Clin Oncol. 2025;43(5_suppl):101.","journal-title":"J Clin Oncol"},{"issue":"26","key":"7737_CR193","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41(26):4267\u201378.","journal-title":"J Clin Oncol"},{"issue":"18","key":"7737_CR194","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, Saatcioglu F. Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management. Theranostics. 2024;14(18):6913\u201334.","journal-title":"Theranostics"},{"issue":"5","key":"7737_CR195","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"7737_CR196","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144\u201353.","journal-title":"Nat Med"},{"issue":"4","key":"7737_CR197","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V, Fl\u00e9chon A, Gravis G, Galsky MD, et al. Nivolumab plus Ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38(4):489\u201399.e3.","journal-title":"Cancer Cell"},{"key":"7737_CR198","doi-asserted-by":"publisher","first-page":"708073","DOI":"10.3389\/fonc.2021.708073","volume":"11","author":"G Zuccolotto","year":"2021","unstructured":"Zuccolotto G, Penna A, Fracasso G, Carpanese D, Montagner IM, Dalla Santa S, et al. PSMA-Specific CAR-Engineered T cells for prostate cancer: CD28 outperforms combined CD28-4-1BB \u201csuper-stimulation\u201d. Front Oncol. 2021;11:708073.","journal-title":"Front Oncol"},{"issue":"10","key":"7737_CR199","doi-asserted-by":"publisher","first-page":"e109427","DOI":"10.1371\/journal.pone.0109427","volume":"9","author":"G Zuccolotto","year":"2014","unstructured":"Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS One. 2014;9(10):e109427.","journal-title":"PLoS One"},{"issue":"3","key":"7737_CR200","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/pros.22749","volume":"74","author":"Q Ma","year":"2014","unstructured":"Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate. 2014;74(3):286\u201396.","journal-title":"Prostate"},{"issue":"2","key":"7737_CR201","doi-asserted-by":"publisher","first-page":"e1380764","DOI":"10.1080\/2162402X.2017.1380764","volume":"7","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764.","journal-title":"Oncoimmunology"},{"key":"7737_CR202","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2407-14-30","volume":"14","author":"V Hillerdal","year":"2014","unstructured":"Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer. 2014;14:30.","journal-title":"BMC Cancer"},{"issue":"1","key":"7737_CR203","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14(1):2041.","journal-title":"Nat Commun"},{"issue":"1","key":"7737_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-014-0064-x","volume":"16","author":"Z Deng","year":"2015","unstructured":"Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015;16(1):1.","journal-title":"BMC Immunol"},{"issue":"5","key":"7737_CR205","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699\u2013715.","journal-title":"Nat Cancer"},{"issue":"2","key":"7737_CR206","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/pcan.2012.49","volume":"16","author":"C Sanchez","year":"2013","unstructured":"Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, et al. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(2):123\u201331, s1.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"7737_CR207","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1210\/js.2018-00425","volume":"3","author":"M Quiroz-Munoz","year":"2019","unstructured":"Quiroz-Munoz M, Izadmehr S, Arumugam D, Wong B, Kirschenbaum A, Levine AC. Mechanisms of osteoblastic bone metastasis in prostate cancer: role of Prostatic acid phosphatase. J Endocr Soc. 2019;3(3):655\u201364.","journal-title":"J Endocr Soc"},{"key":"7737_CR208","doi-asserted-by":"crossref","unstructured":"Cao Z, Pu C, Jiang X, Han G, Shen X, Wang W, et al. Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach. J ImmunoTher Cancer. 2025;13(5).","DOI":"10.1136\/jitc-2024-011238"},{"issue":"11","key":"7737_CR209","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","volume":"10","author":"N Chen","year":"2024","unstructured":"Chen N, Pu C, Zhao L, Li W, Wang C, Zhu R, et al. Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial. JAMA Oncol. 2024;10(11):1532\u201336.","journal-title":"JAMA Oncol"},{"key":"7737_CR210","doi-asserted-by":"publisher","first-page":"1557644","DOI":"10.3389\/fimmu.2025.1557644","volume":"16","author":"J Han","year":"2025","unstructured":"Han J, Wang Y, Chan GC, Chan WK. Designs of NKG2D-based immunotherapeutics for cancer. Front Immunol. 2025;16:1557644.","journal-title":"Front Immunol"},{"key":"7737_CR211","doi-asserted-by":"crossref","unstructured":"He C, Zhou Y, Li Z, Farooq MA, Ajmal I, Zhang H, et al. Co-expression of IL-7 improves NKG2D-Based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion. Cancers (Basel). 2020;12(7).","DOI":"10.3390\/cancers12071969"},{"key":"7737_CR212","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2021.10.041","volume":"525","author":"DS Baek","year":"2022","unstructured":"Baek DS, Kim YJ, Vergara S, Conard A, Adams C, Calero G, et al. A highly-specific fully-human antibody and CAR-T cells targeting CD66e\/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. Cancer Lett. 2022;525:97\u2013107.","journal-title":"Cancer Lett"},{"key":"7737_CR213","doi-asserted-by":"crossref","unstructured":"de Testas de Folmont A, Fauvel A, Vacherot F, Soyeux P, Abdou A, Chouaib S, et al. Targeting aggressive prostate carcinoma cells with mesothelin-CAR-T cells. Biomedicines. 2025;13(5).","DOI":"10.3390\/biomedicines13051215"},{"key":"7737_CR214","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2023.09.018","volume":"680","author":"P Grover","year":"2023","unstructured":"Grover P, Nunez-Cruz S, Leferovich J, Wentz T, Bagchi A, Milone MC, et al. F77 antigen is a promising target for adoptive T cell therapy of prostate cancer. Biochem Biophys Res Commun. 2023;680:51\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"7737_CR215","doi-asserted-by":"crossref","unstructured":"Deller TD, Alzubi J, Mosti L, Peschers M, Gratzke C, Wolf P, et al. Engineering of humanized PSMA-Directed CAR T cells for potent and specific elimination of prostate cancer cells. Cells. 2025;14(17).","DOI":"10.3390\/cells14171333"},{"issue":"5","key":"7737_CR216","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41551-023-01102-5","volume":"8","author":"AV Stepanov","year":"2024","unstructured":"Stepanov AV, Xie J, Zhu Q, Shen Z, Su W, Kuai L, et al. Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells. Nat Biomed Eng. 2024;8(5):529\u201343.","journal-title":"Nat Biomed Eng"},{"issue":"10","key":"7737_CR217","doi-asserted-by":"publisher","first-page":"e1342909","DOI":"10.1080\/2162402X.2017.1342909","volume":"6","author":"E Pishali Bejestani","year":"2017","unstructured":"Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, et al. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunology. 2017;6(10):e1342909.","journal-title":"Oncoimmunology"},{"key":"7737_CR218","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931.","journal-title":"EBioMedicine"},{"issue":"2","key":"7737_CR219","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"7737_CR220","doi-asserted-by":"publisher","first-page":"200789","DOI":"10.1016\/j.omton.2024.200789","volume":"32","author":"KT Kennewick","year":"2024","unstructured":"Kennewick KT, Yamaguchi Y, Gibson J, Gerdts EA, Jeang B, Tilakawardane D, et al. Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells. Mol Ther Oncol. 2024;32(2):200789.","journal-title":"Mol Ther Oncol"},{"issue":"18","key":"7737_CR221","doi-asserted-by":"publisher","first-page":"eadf 0108","DOI":"10.1126\/sciadv.adf0108","volume":"9","author":"JS Frieling","year":"2023","unstructured":"Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, et al. \u03b3\u03b4-enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023;9(18):eadf 0108.","journal-title":"Sci Adv"},{"issue":"10","key":"7737_CR222","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","volume":"188","author":"L Liu","year":"2025","unstructured":"Liu L, He P, Wang Y, Ma F, Li D, Bai Z, et al. Engineering sonogenetic EchoBack-CAR T cells. Cell. 2025;188(10):2621\u201336.e20.","journal-title":"Cell"},{"issue":"6","key":"7737_CR223","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000541881","volume":"103","author":"R Novysedlak","year":"2025","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, et al. The immune microenvironment in prostate cancer: a comprehensive Review. Oncology. 2025;103(6):521\u201345.","journal-title":"Oncology"},{"key":"7737_CR224","doi-asserted-by":"crossref","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng. 2025.","DOI":"10.1038\/s41551-025-01509-2"},{"key":"7737_CR225","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2016.11.005","volume":"4","author":"I Serganova","year":"2017","unstructured":"Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J, et al. Enhancement of PSMA-Directed CAR adoptive immunotherapy by PD-1\/PD-L1 blockade. Mol Ther Oncolytics. 2017;4:41\u201354.","journal-title":"Mol Ther Oncolytics"},{"issue":"8","key":"7737_CR226","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","volume":"77","author":"K Tanoue","year":"2017","unstructured":"Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, et al. Armed Oncolytic adenovirus-expressing PD-L1 Mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017;77(8):2040\u201351.","journal-title":"Cancer Res"},{"key":"7737_CR227","doi-asserted-by":"publisher","first-page":"111339","DOI":"10.1016\/j.biopha.2021.111339","volume":"137","author":"JE Zhou","year":"2021","unstructured":"Zhou JE, Yu J, Wang Y, Wang H, Wang J, Wang Y, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021;137:111339.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7737_CR228","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","volume":"9","author":"S Li","year":"2023","unstructured":"Li S, Zhang M, Wang M, Wang H, Wu H, Mao L, et al. B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer. Cell Death Discov. 2023;9(1):147.","journal-title":"Cell Death Discov"},{"issue":"10","key":"7737_CR229","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1016\/j.ymthe.2024.08.028","volume":"32","author":"I Ajmal","year":"2024","unstructured":"Ajmal I, Farooq MA, Duan Y, Yao J, Gao Y, Hui X, et al. Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer. Mol Ther. 2024;32(10):3539\u201357.","journal-title":"Mol Ther"},{"key":"7737_CR230","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijbiomac.2022.02.094","volume":"206","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Paskeh MDA, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, et al. Transforming growth factor-beta (TGF-\u03b2) in prostate cancer: a dual function mediator? Int J Biol Macromol. 2022;206:435\u201352.","journal-title":"Int J Biol Macromol"},{"key":"7737_CR231","doi-asserted-by":"crossref","unstructured":"Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, et al. Antitumor activity of AZD0754, a dnTgf\u03b2rii-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Invest. 2023;133(22).","DOI":"10.1172\/JCI169655"},{"issue":"7","key":"7737_CR232","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-Targeted human CAR T cell proliferation and augments prostate cancer Eradication. Mol Ther. 2018;26(7):1855\u201366.","journal-title":"Mol Ther"},{"issue":"Pt A","key":"7737_CR233","doi-asserted-by":"publisher","first-page":"110807","DOI":"10.1016\/j.intimp.2023.110807","volume":"124","author":"L Tang","year":"2023","unstructured":"Tang L, Shao H, Wu Y, Wang J, Qian X, He L, et al. Dominant negative TGF\u03b2 receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer. Int Immunopharmacol. 2023;124(Pt A):110807.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"7737_CR234","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","volume":"20","author":"J Wang","year":"2023","unstructured":"Wang J, Zhao X, Wan YY. Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cell Mol Immunol. 2023;20(9):1002\u201322.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"7737_CR235","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","volume":"21","author":"S Weimin","year":"2020","unstructured":"Weimin S, Abula A, Qianghong D, Wenguang W. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol Ther. 2020;21(6):570\u201380.","journal-title":"Cancer Biol Ther"},{"issue":"7714","key":"7737_CR236","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559(7714):363\u201369.","journal-title":"Nature"},{"issue":"1","key":"7737_CR237","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-019-02206-w","volume":"18","author":"D Wang","year":"2020","unstructured":"Wang D, Shao Y, Zhang X, Lu G, Liu B. IL-23 and PSMA-targeted duo-CAR T cells in prostate cancer Eradication in a preclinical model. J Transl Med. 2020;18(1):23.","journal-title":"J Transl Med"},{"key":"7737_CR238","doi-asserted-by":"crossref","unstructured":"Sasaki K, Bhatia V, Asano Y, Bakhtiari J, Kaur P, Wang C, et al. Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models. Nat Biomed Eng. 2025.","DOI":"10.1038\/s41551-025-01508-3"},{"issue":"12","key":"7737_CR239","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1007\/s00432-022-04248-y","volume":"148","author":"X Zhang","year":"2022","unstructured":"Zhang X, Sun S, Miao Y, Yuan Y, Zhao W, Li H, et al. Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs. J Cancer Res Clin Oncol. 2022;148(12):3511\u201320.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7737_CR240","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","volume":"18","author":"J Alzubi","year":"2020","unstructured":"Alzubi J, Dettmer-Monaco V, Kuehle J, Thorausch N, Seidl M, Taromi S, et al. PSMA-Directed CAR T cells combined with low-dose Docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Mol Ther Oncolytics. 2020;18:226\u201335.","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"7737_CR241","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","volume":"29","author":"JP Murad","year":"2021","unstructured":"Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther. 2021;29(7):2335\u201349.","journal-title":"Mol Ther"},{"issue":"1","key":"7737_CR242","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41467-023-40852-3","volume":"14","author":"LH Porter","year":"2023","unstructured":"Porter LH, Zhu JJ, Lister NL, Harrison SG, Keerthikumar S, Goode DL, et al. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nat Commun. 2023;14(1):5346.","journal-title":"Nat Commun"},{"issue":"3","key":"7737_CR243","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43(3):537\u201351.e7.","journal-title":"Cancer Cell"},{"issue":"11\u201312","key":"7737_CR244","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1089\/hum.2024.254","volume":"36","author":"L Fang","year":"2025","unstructured":"Fang L, Wang X, Zhang Y, Zhang C, Liu X, Li W, et al. Oncolytic adenovirus armoring with CXCL9 and IL15 shows potent antitumor activity and boosts CAR-T therapy for prostate cancer. Hum Gene Ther. 2025;36(11\u201312):884\u2013901.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"7737_CR245","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, et al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol Cancer Ther. 2021;20(3):577\u201388.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"7737_CR246","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13104-025-07249-5","volume":"18","author":"NB Pati","year":"2025","unstructured":"Pati NB, Jin Y, Kumar S, Kyte JA, Ciosk R. Thermal potentiation improves IFN-\u03b3 production but not cytotoxicity in human CAR-T cells. BMC Res Notes. 2025;18(1):192.","journal-title":"BMC Res Notes"},{"issue":"6_suppl","key":"7737_CR247","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/jco.2013.31.6_suppl.72","volume":"31","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, Wang X, Hullings M, Arauz G, Bartido S, Lewis JS, et al. Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). J Clin Oncol. 2013;31(6_suppl):72.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7737_CR248","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76(14):1257\u201370.","journal-title":"Prostate"},{"issue":"6","key":"7737_CR249","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30(6):1636\u201344.","journal-title":"Nat Med"},{"issue":"1","key":"7737_CR250","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","volume":"15","author":"MN Stein","year":"2024","unstructured":"Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, et al. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024;15(1):10743.","journal-title":"Nat Commun"},{"key":"7737_CR251","doi-asserted-by":"crossref","unstructured":"Locke FL, Nikiforow S, Frigault MJ, Maloney DG, Davila M, Miklos DB, et al. Recommendations for defining chimeric antigen receptor T-Cell (CAR T) dose-limiting toxicities (DLTs) for future early-phase CAR T therapy studies. Transpl Cell Ther. 2025.","DOI":"10.1016\/j.jtct.2025.11.004"},{"issue":"2","key":"7737_CR252","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","volume":"26","author":"D Pettitt","year":"2018","unstructured":"Pettitt D, Arshad Z, Smith J, Stanic T, Holl\u00e4nder G, Brindley D. CAR-T cells: a Systematic Review and mixed methods analysis of the clinical trial landscape. Mol Ther. 2018;26(2):342\u201353.","journal-title":"Mol Ther"},{"issue":"2","key":"7737_CR253","doi-asserted-by":"publisher","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","volume":"33","author":"L Abdo","year":"2025","unstructured":"Abdo L, Batista-Silva LR, Bonamino MH. Cost-effective strategies for CAR-T cell therapy manufacturing. Mol Ther Oncol. 2025;33(2):200980.","journal-title":"Mol Ther Oncol"},{"key":"7737_CR254","doi-asserted-by":"publisher","first-page":"1005457","DOI":"10.3389\/fimmu.2022.1005457","volume":"13","author":"N Martinez-Cibrian","year":"2022","unstructured":"Martinez-Cibrian N, Espa\u00f1ol-Rego M, Pascal M, Delgado J, Ortiz-Maldonado V. Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing. Front Immunol. 2022;13:1005457.","journal-title":"Front Immunol"},{"issue":"4","key":"7737_CR255","first-page":"e271.1","volume":"31","author":"CB Grady","year":"2025","unstructured":"Grady CB, Li Y, Maude SL, Hexner EO, Frey NV, Porter DL, et al. Inconsistent reporting and definitions of time-to-event Endpoints in CAR T clinical trials: a Review. Transpl Cell Ther. 2025;31(4):e271.1\u2013.13.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"7737_CR256","doi-asserted-by":"publisher","first-page":"e1003894","DOI":"10.1371\/journal.pmed.1003894","volume":"19","author":"M Mitra-Majumdar","year":"2022","unstructured":"Mitra-Majumdar M, Kesselheim AS. Reporting bias in clinical trials: progress toward transparency and next steps. PLoS Med. 2022;19(1):e1003894.","journal-title":"PLoS Med"},{"issue":"11","key":"7737_CR257","doi-asserted-by":"publisher","first-page":"e2343425","DOI":"10.1001\/jamanetworkopen.2023.43425","volume":"6","author":"LM Siena","year":"2023","unstructured":"Siena LM, Papamanolis L, Siebert MJ, Bellomo RK, Ioannidis JPA. Industry involvement and transparency in the most cited clinical trials, 2019-2022. JAMA Netw Open. 2023;6(11):e2343425.","journal-title":"JAMA Netw Open"},{"issue":"23","key":"7737_CR258","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1182\/bloodadvances.2025017011","volume":"9","author":"S Naik","year":"2025","unstructured":"Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, et al. International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025;9(23):6047\u201358.","journal-title":"Blood Adv"},{"issue":"9","key":"7737_CR259","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, et al. NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2. 2024. J Natl Compr Canc Netw. 2024;22(9):582\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"7737_CR260","doi-asserted-by":"crossref","unstructured":"Gautam S, Gautam B, Shilpakar R, Cs K, Kurmi OP. CAR-T cell therapy in developing countries: how long should we wait? J ImmunoTher Cancer. 2024;12(12).","DOI":"10.1136\/jitc-2024-009611"},{"issue":"33","key":"7737_CR261","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1200\/JCO.24.00843","volume":"42","author":"JM Unger","year":"2024","unstructured":"Unger JM, Xiao H, Vaidya R, LeBlanc M. Patient enrollment to Industry-Sponsored versus federally-Sponsored cancer clinical trials. J Clin Oncol. 2024;42(33):3917\u201325.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7737_CR262","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cmi.2015.07.004","volume":"21","author":"PF Laterre","year":"2015","unstructured":"Laterre PF, Fran\u00e7ois B. Strengths and limitations of industry vs. academic randomized controlled trials. Clin Microbiol Infect. 2015;21(10):906\u201309.","journal-title":"Clin Microbiol Infect"},{"issue":"18","key":"7737_CR263","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","volume":"9","author":"AP Chung","year":"2025","unstructured":"Chung AP, Shafrin JT, Vadgama S, Hurley K, Perales MA, Alsfeld LC, et al. Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-Medicare data analysis. Blood Adv. 2025;9(18):4727\u201335.","journal-title":"Blood Adv"},{"key":"7737_CR264","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z, et al. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine. 2024;73:102684.","journal-title":"EClinicalMedicine"},{"key":"7737_CR265","doi-asserted-by":"crossref","unstructured":"Chen H, Weng Y, Zheng D, Li T, Xu N, Kang L, et al. Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine. J Adv Res. 2025.","DOI":"10.1016\/j.jare.2025.10.026"},{"issue":"1","key":"7737_CR266","first-page":"21","volume":"11","author":"DC Feng","year":"2024","unstructured":"Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11(1):21.","journal-title":"Mil Med Res"},{"issue":"1","key":"7737_CR267","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41392-023-01362-2","volume":"8","author":"J Hu","year":"2023","unstructured":"Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, Reynoso JG, et al. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther. 2023;8(1):155.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"7737_CR268","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1158\/1078-0432.CCR-12-1807","volume":"18","author":"CD Hurst","year":"2012","unstructured":"Hurst CD, Platt FM, Taylor CF, Knowles MA. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res. 2012;18(21):5865\u201377.","journal-title":"Clin Cancer Res"},{"key":"7737_CR269","first-page":"e18761429350210","volume":"17","author":"AS Carranza-Aranda","year":"2024","unstructured":"Carranza-Aranda AS, Santerre A, Segura-Cabrera A, C\u00e1rdenas-Vargas A, Mart\u00ednez-Vel\u00e1zquez M, Hern\u00e1ndez-Guti\u00e9rrez R, et al. Chrysin: a potential Antiandrogen ligand to mutated androgen receptors in prostate cancer. Curr Mol Pharmacol. 2024;17:e18761429350210.","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"7737_CR270","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019;76(1):89\u201397.","journal-title":"Eur Urol"},{"issue":"9","key":"7737_CR271","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/labinvest.2008.65","volume":"88","author":"HM Kluger","year":"2008","unstructured":"Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest. 2008;88(9):962\u201372.","journal-title":"Lab Invest"},{"issue":"12","key":"7737_CR272","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","volume":"42","author":"H Hamidi","year":"2024","unstructured":"Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell. 2024;42(12):2098\u2013112.e4.","journal-title":"Cancer Cell"},{"issue":"1","key":"7737_CR273","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.","journal-title":"Mol Cancer"},{"issue":"2","key":"7737_CR274","first-page":"e70000","volume":"17","author":"F Moradi Kashkooli","year":"2025","unstructured":"Moradi Kashkooli F, Mirala F, Hht M, Alirahimi M, Souri M, Golzaryan A, et al. Mechanical forces in tumor growth and treatment: perspectives from biology. Phys, Eng, Math Modeling. WIREs Mech Dis. 2025;17(2):e70000.","journal-title":"Phys, Eng, Math Modeling. WIREs Mech Dis"},{"issue":"4","key":"7737_CR275","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1464-410X.2005.05357.x","volume":"95","author":"E Ioachim","year":"2005","unstructured":"Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int. 2005;95(4):655\u201359.","journal-title":"BJU Int"},{"issue":"9","key":"7737_CR276","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/1078-0432.CCR-17-2210","volume":"24","author":"AR Elia","year":"2018","unstructured":"Elia AR, Grioni M, Basso V, Curnis F, Freschi M, Corti A, et al. Targeting tumor vasculature with TNF Leads effector T cells to the tumor and enhances therapeutic efficacy of immune checkpoint blockers in combination with adoptive cell therapy. Clin Cancer Res. 2018;24(9):2171\u201381.","journal-title":"Clin Cancer Res"},{"key":"7737_CR277","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fimmu.2012.00021","volume":"3","author":"S Chouaib","year":"2012","unstructured":"Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21.","journal-title":"Front Immunol"},{"key":"7737_CR278","doi-asserted-by":"publisher","first-page":"e18761429266116","DOI":"10.2174\/0118761429266116231123160809","volume":"17","author":"CL Yin","year":"2024","unstructured":"Yin CL, Ma YJ. The regulatory Mechanism of hypoxia-inducible factor 1 and its clinical significance. Curr Mol Pharmacol. 2024;17:e18761429266116.","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"7737_CR279","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1096\/fj.14-250985","volume":"29","author":"H Huang","year":"2015","unstructured":"Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-\u03baB-induced endothelial activation. FASEB J. 2015;29(1):227\u201338.","journal-title":"Faseb J"},{"issue":"2 Pt 1","key":"7737_CR280","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/01.ju.0000074870.54671.98","volume":"170","author":"X Na","year":"2003","unstructured":"Na X, Wu G, Ryan CK, Schoen SR, Di\u2019santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003;170(2 Pt 1):588\u201392.","journal-title":"J Urol"},{"issue":"2","key":"7737_CR281","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139\u201348.","journal-title":"J Exp Med"},{"key":"7737_CR282","doi-asserted-by":"crossref","unstructured":"Lasorsa F, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, et al. Cellular and molecular players in the tumor microenvironment of renal cell carcinoma. J Clin Med. 2023;12(12).","DOI":"10.3390\/jcm12123888"},{"key":"7737_CR283","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156\u201369.","journal-title":"Cancer Lett"},{"issue":"3","key":"7737_CR284","doi-asserted-by":"publisher","first-page":"446","DOI":"10.21147\/j.issn.1000-9604.2025.03.12","volume":"37","author":"J Zou","year":"2025","unstructured":"Zou J, Wang S, Zhang Y, Tian W, Mai G, Xu Y, et al. Tumor-educated cells in tumor microenvironment: key drivers of immunotherapy resistance. Chin J Cancer Res. 2025;37(3):446\u201365.","journal-title":"Chin J Cancer Res"},{"issue":"33","key":"7737_CR285","doi-asserted-by":"publisher","first-page":"e2402903121","DOI":"10.1073\/pnas.2402903121","volume":"121","author":"G Yu","year":"2024","unstructured":"Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, et al. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A. 2024;121(33):e2402903121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"7737_CR286","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-22-3034","volume":"83","author":"G Davidson","year":"2023","unstructured":"Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, et al. Mesenchymal-like tumor cells and Myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear cell renal cell carcinoma. Cancer Res. 2023;83(17):2952\u201369.","journal-title":"Cancer Res"},{"issue":"3","key":"7737_CR287","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","volume":"75","author":"van Dijk N","year":"2019","unstructured":"van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. Eur Urol. 2019;75(3):435\u201344.","journal-title":"Eur Urol"},{"issue":"8","key":"7737_CR288","doi-asserted-by":"publisher","first-page":"881","DOI":"10.20892\/j.issn.2095-3941.2025.0149","volume":"22","author":"L Zhang","year":"2025","unstructured":"Zhang L, Fu J, Liu X, Feng S, Leng Y. The immune landscape of systemic inflammation in prostate cancer. Cancer Biol Med. 2025;22(8):881\u2013902.","journal-title":"Cancer Biol Med"},{"key":"7737_CR289","doi-asserted-by":"publisher","first-page":"1685237","DOI":"10.3389\/fimmu.2025.1685237","volume":"16","author":"L Lu","year":"2025","unstructured":"Lu L, Wang F, Wang Z, Guo S, Jiang M, Ma Z. Immune snapshots along the inflammation-to-cancer road in bladder urothelium. Front Immunol. 2025;16:1685237.","journal-title":"Front Immunol"},{"key":"7737_CR290","doi-asserted-by":"crossref","unstructured":"Afonso J, Gon\u00e7alves C, Costa M, Ferreira D, Santos L, Longatto-Filho A, et al. Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as Prognostic biomarker and target for bladder cancer therapy. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030982"},{"key":"7737_CR291","doi-asserted-by":"crossref","unstructured":"Wang Y, Chen Y, Wang J. Role of tumor microenvironment in prostate cancer immunometabolism. Biomolecules. 2025;15(6).","DOI":"10.3390\/biom15060826"},{"key":"7737_CR292","doi-asserted-by":"publisher","first-page":"e18761429308361","DOI":"10.2174\/0118761429308361240823061634","volume":"17","author":"L Qiong","year":"2024","unstructured":"Qiong L, Shuyao X, Shan X, Qian F, Jiaying T, Yao X, et al. Recent advances in the glycolytic processes linked to tumor metastasis. Curr Mol Pharmacol. 2024;17:e18761429308361.","journal-title":"Curr Mol Pharmacol"},{"issue":"15","key":"7737_CR293","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.7150\/ijbs.123647","volume":"21","author":"Z Li","year":"2025","unstructured":"Li Z, Yang L, Li W, Huang W, Ma C, Sun B, et al. Metabolic reprogramming in urological tumors: new Perspectives from tumor metabolic phenotypes to therapeutic targets. Int J Biol Sci. 2025;21(15):6926\u201351.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"7737_CR294","doi-asserted-by":"publisher","first-page":"432","DOI":"10.21147\/j.issn.1000-9604.2025.03.11","volume":"37","author":"L Sun","year":"2025","unstructured":"Sun L, Zhao G, Wang S, Li N. Immune cell metabolism in cancer drug resistance: advances in target discovery and clinical translation. Chin J Cancer Res. 2025;37(3):432\u201345.","journal-title":"Chin J Cancer Res"},{"issue":"11","key":"7737_CR295","doi-asserted-by":"publisher","first-page":"108500","DOI":"10.1016\/j.celrep.2020.108500","volume":"33","author":"WJ Quinn 3rd","year":"2020","unstructured":"Quinn WJ 3rd, Jiao J, TeSlaa T, Stadanlick J, Wang Z, Wang L, et al. Lactate limits T cell proliferation via the NAD(H) redox state. Cell Rep. 2020;33(11):108500.","journal-title":"Cell Rep"},{"issue":"35","key":"7737_CR296","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO Guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7737_CR297","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA. CAR T-Cell associated neurotoxicity: mechanisms, clinicopathologic Correlates, and future directions. J Natl Cancer Inst. 2019;111(7):646\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7737_CR298","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"7737_CR299","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"7737_CR300","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cancergen.2024.09.002","volume":"288-289","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang J, Zeng T, Qi J. Data-mining-based biomarker evaluation and experimental validation of SHTN1 for bladder cancer. Cancer Genet. 2024;288-289:43\u201353.","journal-title":"Cancer Genet"},{"issue":"1","key":"7737_CR301","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21147\/j.issn.1000-9604.2025.01.07","volume":"37","author":"T Ding","year":"2025","unstructured":"Ding T, He L, Lin G, Xu L, Zhu Y, Wang X, et al. Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer. Chin J Cancer Res. 2025;37(1):90\u2013114.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"7737_CR302","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","volume":"23","author":"J Wu","year":"2024","unstructured":"Wu J, Lin Y, Yang K, Liu X, Wang H, Yu T, et al. Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial. Mol Cancer. 2024;23(1):57.","journal-title":"Mol Cancer"},{"issue":"3","key":"7737_CR303","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1002\/wsbm.70001","volume":"17","author":"N Rajinikanth","year":"2025","unstructured":"Rajinikanth N, Chauhan R, Prabakaran S. Harnessing noncanonical proteins for next-generation Drug discovery and diagnosis. WIREs Mech Dis. 2025;17(3):e70001.","journal-title":"WIREs Mech Dis"},{"key":"7737_CR304","doi-asserted-by":"crossref","unstructured":"Xiong Z, Kong Q, Chagantipati B, Stepniak A, Jaswal AP, Sneiderman CT, et al. C\/EBP\u03b2-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma. Cell Mol Immunol. 2025.","DOI":"10.1038\/s41423-025-01360-0"},{"issue":"18","key":"7737_CR305","doi-asserted-by":"publisher","first-page":"e2211509","DOI":"10.1002\/adma.202211509","volume":"35","author":"X Tang","year":"2023","unstructured":"Tang X, Yang Y, Zheng M, Yin T, Huang G, Lai Z, et al. Magnetic-acoustic sequentially actuated CAR T cell microrobots for Precision navigation and in situ antitumor immunoactivation. Adv Mater. 2023;35(18):e2211509.","journal-title":"Adv Mater"},{"key":"7737_CR306","doi-asserted-by":"publisher","first-page":"107190","DOI":"10.1016\/j.ejps.2025.107190","volume":"213","author":"RS Pivetta","year":"2025","unstructured":"Pivetta RS, de Campos NSP, Kinker GS, Beserra AO, Marasco WA, Medina TDS, et al. PD-L1 downregulation by carbonic anhydrase IX immunotherapy prompts immune checkpoint blockade in renal cell carcinoma. Eur J Pharm Sci. 2025;213:107190.","journal-title":"Eur J Pharm Sci"},{"key":"7737_CR307","doi-asserted-by":"crossref","unstructured":"Zuo Y, Vohwinkel DJ, Dong B, McDowell JR, Guzman BV, Manickavel Pandian TS, et al. IL-36\u03b3 armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity. Cancer Cell. 2025.","DOI":"10.1016\/j.ccell.2025.11.007"},{"issue":"22","key":"7737_CR308","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","volume":"188","author":"Z Wu","year":"2025","unstructured":"Wu Z, Shi J, Lamao Q, Qiu Y, Yang J, Liu Y, et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell. 2025;188(22):6317\u201334.e21.","journal-title":"Cell"},{"issue":"8075","key":"7737_CR309","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","volume":"644","author":"AXY Chen","year":"2025","unstructured":"Chen AXY, Yap KM, Kim JS, Sek K, Huang YK, Dunbar PA, et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature. 2025;644(8075):241\u201351.","journal-title":"Nature"},{"key":"7737_CR310","first-page":"0917","volume":"8","author":"M Lai","year":"2025","unstructured":"Lai M, Shao W, Mao J, Ye Q. Revolution in cell therapy: In Vivo chimeric-antigen-receptor-T-Cell therapy breakthroughs and promises for the future. Res (Wash D C). 2025;8:0917.","journal-title":"Res (Wash D C)"},{"issue":"6753","key":"7737_CR311","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u201317.","journal-title":"Science"},{"issue":"9","key":"7737_CR312","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1097\/JS9.0000000000002805","volume":"111","author":"Y Chen","year":"2025","unstructured":"Chen Y, Long T, Wang M, Liu S, Lv Z, Jiang Y, et al. Prospective cohort study integrating plasma proteomics and machine learning for early risk prediction of prostate cancer. Int J Surg. 2025;111(9):6123\u201334.","journal-title":"Int J Surg"},{"issue":"22","key":"7737_CR313","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1182\/bloodadvances.2025016375","volume":"9","author":"M Wang","year":"2025","unstructured":"Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, et al. An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL. Blood Adv. 2025;9(22):5837\u201352.","journal-title":"Blood Adv"},{"issue":"12","key":"7737_CR314","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-Cell therapy. JAMA Neurol. 2020;77(12):1536\u201342.","journal-title":"JAMA Neurol"},{"key":"7737_CR315","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.1182\/blood-2024-203356","volume":"144","author":"P Lafeuille","year":"2024","unstructured":"Lafeuille P, Shafquat A, Sang C, Beigi M, Maura F, Aptekar J. Using synthetic data produced by Artificial intelligence (AI) to generate insights for chimeric antigen receptor T-Cell (CAR T-Cell) clinical trials. Blood. 2024;144:7484.","journal-title":"Blood"},{"issue":"5","key":"7737_CR316","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu S, Chen J, Wu T, Li L, Wang G, Wu H, et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 2024;34(5):386\u201388.","journal-title":"Cell Res"},{"issue":"8016","key":"7737_CR317","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493\u2013500.","journal-title":"Nature"},{"key":"7737_CR318","doi-asserted-by":"publisher","first-page":"913287","DOI":"10.3389\/fmed.2022.913287","volume":"9","author":"S Hort","year":"2022","unstructured":"Hort S, Herbst L, B\u00e4ckel N, Erkens F, Niessing B, Frye M, et al. Toward rapid, widely available autologous CAR-T cell therapy - Artificial intelligence and automation enabling the smart manufacturing Hospital. Front Med (Lausanne). 2022;9:913287.","journal-title":"Front Med (Lausanne)"},{"key":"7737_CR319","unstructured":"Zhavoronkov A, Leung CY. Engineering the future of longevity R & amp;D: The case for AI-Driven, integrated biotechnology ecosystems. Aging Dis. 2025."},{"issue":"1","key":"7737_CR320","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41467-025-56784-z","volume":"16","author":"Y Xiong","year":"2025","unstructured":"Xiong Y, Yao L, Lin J, Yao J, Bai Q, Huang Y, et al. Artificial intelligence links CT images to pathologic features and survival outcomes of renal masses. Nat Commun. 2025;16(1):1425.","journal-title":"Nat Commun"},{"issue":"10","key":"7737_CR321","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.cell.2024.03.035","volume":"187","author":"AH Song","year":"2024","unstructured":"Song AH, Williams M, Williamson DFK, Chow SSL, Jaume G, Gao G, et al. Analysis of 3D pathology samples using weakly supervised AI. Cell. 2024;187(10):2502\u201320.e17.","journal-title":"Cell"},{"key":"7737_CR322","doi-asserted-by":"crossref","unstructured":"Eguren-Santamaria I, Melero IP, Rodr\u00edguez I, Ortego I, Armero M, Galvez-Cancino F, et al. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. J ImmunoTher Cancer. 2025;13(10).","DOI":"10.1136\/jitc-2024-011279"},{"issue":"4","key":"7737_CR323","doi-asserted-by":"publisher","first-page":"20230126","DOI":"10.1002\/EXP.20230126","volume":"4","author":"G Wang","year":"2024","unstructured":"Wang G, Mao X, Wang W, Wang X, Li S, Wang Z. Bioprinted research models of urological malignancy. Exploration (Beijing). 2024;4(4):20230126.","journal-title":"Exploration (Beijing)"},{"issue":"9","key":"7737_CR324","doi-asserted-by":"publisher","first-page":"12963","DOI":"10.1096\/fj.202001203R","volume":"34","author":"C Ye","year":"2020","unstructured":"Ye C, Yang H, Cheng M, Shultz LD, Greiner DL, Brehm MA, et al. A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome. Faseb J. 2020;34(9):12963\u201375.","journal-title":"Faseb J"},{"key":"7737_CR325","doi-asserted-by":"publisher","first-page":"115135","DOI":"10.1016\/j.addr.2023.115135","volume":"203","author":"L Liu","year":"2023","unstructured":"Liu L, Yoon CW, Yuan Z, Guo T, Qu Y, He P, et al. Cellular and molecular imaging of CAR-T cell-based immunotherapy. Adv Drug Deliv Rev. 2023;203:115135.","journal-title":"Adv Drug Deliv Rev"},{"key":"7737_CR326","doi-asserted-by":"crossref","unstructured":"Ikhapoh I, Atairu U, Reich AJ, Mantia CM, Wei XX, Sekar R, et al. Examining patient characteristics in bladder cancer clinical trials involving immunotherapy. J Clin Med. 2025;14(3).","DOI":"10.3390\/jcm14030879"},{"key":"7737_CR327","doi-asserted-by":"publisher","first-page":"115145","DOI":"10.1016\/j.ejca.2024.115145","volume":"214","author":"M Gu\u00e9gan","year":"2025","unstructured":"Gu\u00e9gan M, Bichon M, Chaput N, Houot R, Lemoine J. Cancer immunotherapy in elderly patients: the concept of immune senescence challenged by clinical experience. Eur J Cancer. 2025;214:115145.","journal-title":"Eur J Cancer"},{"issue":"7","key":"7737_CR328","first-page":"358","volume":"28","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transpl Cell Ther. 2022;28(7):358\u201364.","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"7737_CR329","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","volume":"6","author":"W Jing","year":"2025","unstructured":"Jing W, Han M, Wang G, Kong Z, Zhao X, Fu Z, et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat Cancer. 2025;6(5):838\u201353.","journal-title":"Nat Cancer"},{"key":"7737_CR330","doi-asserted-by":"crossref","unstructured":"Ibrahim A, Liang Z, Liu W, Di X, Rabiu L, Li R, et al. CD86 costimulation enhances the antitumor activity of NKG2D CAR-Macrophages and synergizes with anti-PD-L1 therapy to suppress prostate cancer progression. Cell Commun Signal. 2025.","DOI":"10.1186\/s12964-025-02548-7"},{"key":"7737_CR331","doi-asserted-by":"crossref","unstructured":"Qiu Z, Li Z, Zhang C, Zhao Q, Liu Z, Cheng Q, et al. NK cell senescence in cancer: from molecular mechanisms to therapeutic opportunities. Aging Dis. 2025.","DOI":"10.14336\/AD.2025.0053"},{"issue":"1","key":"7737_CR332","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Y, He X, Mo Z, Zhao M, Liang X, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell Rep Med. 2025;6(1):101889.","journal-title":"Cell Rep Med"},{"issue":"3","key":"7737_CR333","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"issue":"5","key":"7737_CR334","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W, et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer. 2025;6(5):786\u2013800.","journal-title":"Nat Cancer"},{"key":"7737_CR335","unstructured":"Xu Y, Zhang X, Han X, Huang H, Meng C, Yang Y, et al. Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. Cell. 2025."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07737-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:02:46Z","timestamp":1773064966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":335,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7737"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07737-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"333"}}